NEW YORK, June 28 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Insulin Delivery Systems industry
http://www.reportlinker.com/p0197201/Global-Insulin-Delivery-Systems-industry.html
This report analyzes the worldwide markets for Insulin Delivery Systems in US$ Million by the following major Insulin Delivery Mechanisms - Insulin Syringes, Insulin Pumps (External), and Insulin Pens. The report provides separate comprehensive analytics for US, Europe, and Rest of World. Annual forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 72 companies including many key and niche players worldwide such as Animas Corporation, Antares Pharma, Inc., Becton, Dickinson and Company, Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Disetronic Medical Systems, Inc., Generex Biotechnology Corp., Insulet Corp, Medical Plastic Devices Inc., Medtronic Inc., Novo Nordisk A/S, Patton Medical Devices, LP, Sanofi-Aventis, Smiths Medical MD, Inc., and Ypsomed AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
INSULIN DELIVERY SYSTEMS MCP-6283
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Increasing Diabetes Prevalence - A Major Growth Propeller II-1
Diabetes - Taking Toll in Developing Countries II-1
Insulin Therapy for Diabetes Management II-2
Insulin Delivery Systems - A Quick Market Primer II-2
Insulin Pump Therapy: Convenient Alternate to Insulin Injection II-3
United States - The Largest Global Market for Insulin Pumps
(External) II-3
Rosy Future Ahead for Insulin Pens II-3
Select Brands of Disposable Insulin Pens by Manufacturer II-4
Select Brands of Reusable Insulin Pens by Manufacturer II-4
Innovations in Insulin Delivery - An Overview II-4
Select Next-Generation Insulin Delivery Techniques and Devices II-5
Pulmonary Insulin Delivery via Inhalers II-5
Early Jitters Make Pharma Majors Abandon Inhaled Insulin
Research II-5
Pulmonary Insulin Delivery Research Still Remains Unabated II-6
Transdermal Delivery of Insulin via Patches II-6
Transmucosal Insulin Delivery via Mouth Spray II-7
Nasal Delivery of Insulin via Nasal Mucosa II-7
Hydrogels for Insulin Delivery II-7
Oral Insulin Delivery II-8
Artificial Pancreas Technology - A Promising Approach for
Diabetes Treatment II-8
Competitive Landscape II-9
Insulin Syringes II-9
Insulin Pumps II-9
Insulin Pens II-9
2. MAJOR TRENDS & ISSUES II-10
Pre-Filled Syringes: Gaining Diabetics Attention II-10
Insulin Pumps Market: Tough Ground for New Entrants II-10
Innovative Features Spruce Up the Market for Insulin Pumps II-10
Combination Products: The Latest Trend in the Insulin Pump Market II-12
Implantable Insulin Pumps: Emerging Technology in the Insulin
Pump Market II-12
Expiry of Warranty Provides New Opportunities to Insulin Pump
Makers II-12
Insulin Pump Market Issues II-13
Insulin Pump Training Not Receiving Adequate Attention II-13
Complicated Insulin Pump Software Makes Pump Use Difficult
for the Aged II-13
3. DIABETES & INSULIN DELIVERY SYSTEMS - AN ABSTRACT II-14
Diabetes - A Fatal Disease II-14
Risk Factors for Diabetes II-14
Types of Diabetes II-14
Type I Diabetes: Insulin-Dependent Diabetes Mellitus (IDDM) II-14
Type II Diabetes: Non Insulin-Dependent Diabetes Mellitus
(NIDDM) II-15
Long Term Complications of Diabetes II-15
Pancreas: The Main Source of Insulin in Human Body II-16
Types of Insulin & Administration II-16
Oral Administration II-17
Goal of Insulin Therapy II-17
Insulin Delivery Systems - An Overview II-17
Insulin Syringes II-18
Insulin Needles II-18
Insulin Pens II-18
Advantages of Insulin Pens II-19
Disadvantages of Insulin Pens II-19
External Insulin Pumps II-19
Insulin Pump Components II-19
How Does an Insulin Pump Work? II-20
Insulin Pump Delivery Rates II-20
Advantages of Insulin Pumps II-21
More Accurate and Consistent II-21
Adjusting Time Zones While Traveling II-21
Enhances Blood Sugar Control in Pediatric Patients II-21
Improves Quality of Life II-21
Disadvantages of Insulin Pumps II-21
High Cost II-21
High Involvement II-21
Diabetic Ketoacidosis Risk II-22
Glucose Testing at Regular Intervals II-22
Regular Rotation of Infusion Set II-22
Carrying Back-up Kit II-22
Regular Refilling of Pump II-22
Insulin Jet Injectors II-22
Pen Injectors II-23
4. RESEARCH & DEVELOPMENT II-24
Nanotechnology Victoria, Monash University Develop SAW
Generated Mechanism, for Insulin Delivery II-24
Medtronic Emphasizes Cutting-Edge Features of a Closed-Loop
Diabetes Management System, Currently Under Development II-24
Toray Industries and Hoshi University Discover a New Approach
for Insulin Delivery Via Nasal Spray II-24
A New Study Demonstrates Superior Benefits of Novo Nordisk's
Next Generation II-25
Phosphagenics to Commence Phase II Clinical Trials of
Transdermal Insulin Delivery System II-25
Oramed Pharmaceuticals Begins Phase Ia Trials of Insulin
Suppository II-25
Debiotech and STMicroelectronics Unveil First Prototype of a
Disposable Insulin Nanopump II-25
Braunschweig University Scholar Devises Wristwatch Insulin Pump II-26
5. PRODUCT INTRODUCTIONS II-27
Novo Nordisk Introduces Preloaded Pen II-27
BD Medical Unveils BD AutoShield Pen Needle II-27
Novo Nordisk Introduces Flexpen II-27
Polymedicure Unveils Insulin syringes II-27
Johnson & Johnson Medical India to Unveil Insulin Pumps II-27
Generex Rolls Out Oral Insulin Spray II-27
Eli Lilly Launches KwikPen II-28
Smith Medical Launches Cozmo in China II-28
Medtronic Unveils Arabic Language Insulin Pump II-28
Medtronic Launches New Diabetes Monitoring System II-29
Eli Lilly to Unveil New Insulin Pen, Memoir II-29
6. RECENT INDUSTRY ACTIVITY II-30
JDRF Enters into Partnership with Animas II-30
Medtronic Acquires Certain Assets from PreciSense II-30
MannKind Inks Agreement to Acquire Pfizer's German Insulin
Facility II-30
Owen Mumford Inks Deal with Sanofi-Aventis II-30
Medingo Obtains FDA Approval for Marketing Insulin Micropump II-31
Insulet Wins CE Mark Approval for OmniPod® Insulin Management
System II-31
Sanofi-aventis Receives FDA Approval for Apidra® SoloSTAR® II-31
Novo Nordisk Receives FDA Approval for NovoLog® Labeling Change II-31
Patton Medical Devices, Unomedical Enter into Partnership
Agreement II-32
Sanofi-aventis Wins Canadian and EU Approval for ClikSTAR®
Insulin Pen II-32
DexCom and Animas Amend Insulin Pump Joint Development Deal II-32
Medingo Secures FDA Approval for Solo MicroPump Insulin
Delivery System II-32
Qualitest Pharmaceuticals Recalls Accusure Insulin Syringes II-33
Novartis Completes Acquisition of Nektar's Pulmonary Business II-33
Smiths Medical Acquires Zhejiang Zheda Medical Instrument II-33
ICBS Acquires Vectoris Pharma II-33
Sagent Pharma Acquires Rights to ChaSyr, a Multi-Chamber Syringe II-34
Novo Nordisk Hands Over Inhaled Insulin Patents to Aradigm II-34
Eli Lilly and Alkermes Terminate Inhaled Insulin Development Deal II-34
Novo-Nordisk Drops Development Plan of Inhaled Insulin II-34
Generex, Dongsung Pharm Enter Agreement for Generex Oral-lyn II-34
Novo Nordisk Gains FDA Clearance for NovoLog® II-35
Novo Nordisk to Construct Insulin Plant in China II-35
Generex Biotechnology Enters into Distribution Agreement with
SciGen II-35
Rexam and Eli Lilly to Expand Manufacturing Base for Insulin Pens II-35
Merrion to Develop and Market Novo Nordisk's Insulin Analogues II-35
Smiths Medical to Cease Insulin Pumps Sale, Exist Diabetes
Business II-36
Covidien Recalls Mislabelled Syringes II-36
Animas Recalls Insulin Pumps with Faulty Battery Cap II-36
NationsHealth Acquires Diabetes Care & Education II-36
Insulet Inks Agreement with DexCom II-37
Insulet Partners with Flextronics II-37
Debiotech Allies with STMicroelectronics II-37
SpectRx Divests Insulin Pump Business II-37
7. FOCUS ON SELECT GLOBAL PLAYERS II-38
Animas Corporation (USA) II-38
Antares Pharma, Inc. (USA) II-38
Becton, Dickinson and Company (USA) II-39
Eli Lilly and Company (USA) II-39
F. Hoffmann-La Roche, Ltd. (Switzerland) II-40
Disetronic Medical Systems, Inc. (USA) II-40
Generex Biotechnology Corp. (Canada) II-41
Insulet Corp. (USA) II-41
Medical Plastic Devices Inc. (Canada) II-42
Medtronic Inc. (USA) II-42
Novo Nordisk A/S (Denmark) II-43
Patton Medical Devices, LP (USA) II-43
Sanofi-Aventis (France) II-43
Smiths Medical MD, Inc. (USA) II-44
Ypsomed AG (Switzerland) II-44
8. GLOBAL MARKET PERSPECTIVE II-45
Insulin Syringes: II-45
Table 1: World Recent Past, Current & Future Analysis for
Insulin Syringes Market by Geographic Region - US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) II-45
Table 2: World Historic Review for Insulin Syringes Market by
Geographic Region - US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) II-46
Table 3: World 15-year Perspective for Insulin Syringes Market
by Geographic Region - Percentage Breakdown of Value Sales for
US, Europe and Rest of World Markets for Years 2003, 2009 &
2015 (includes corresponding Graph/Chart) II-47
Insulin Pumps (External): II-48
Table 4: World Recent Past, Current & Future Analysis for
Insulin Pumps (External) Market by Geographic Region - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) II-48
Table 5: World Historic Review for Insulin Pumps (External)
Market by Geographic Region - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) II-49
Table 6: World 15-year Perspective for Insulin Pumps
(External) Market by Geographic Region - Percentage Breakdown
of Value Sales for US, Europe and Rest of World Markets for
Years 2003, 2009 & 2015 (includes corresponding Graph/Chart) II-50
Insulin Pens: II-51
Table 7: US and Europe Recent Past, Current & Future Analysis
for Insulin Pens Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) II-51
Table 8: US and Europe Historic Review for Insulin Pens
Markets IndependentlyAnalyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) II-51
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Diabetes - A Cause of Concern III-1
Table 9: Diabetes Prevalence by Diabetes Type in Millions
in the US (2008) (includes corresponding Graph/Chart) III-1
Surging Diabetic Population Keeps Demand Ticking for Insulin
Delivery Systems III-1
External Insulin Pumps: A Key Mechanism for Insulin Delivery III-2
Insulin Pens Gaining Immense Prominence III-2
Jet Injectors: The Costliest Insulin Delivery System III-2
Competitive Analysis by Insulin Delivery System III-3
Becton Dickinson - The Insulin Syringes Market Leader III-3
Table 10: US Insulin Syringes Market (2007): Percentage
Share Breakdown by Leading Companies - Becton Dickinson,
Kendall, and Others (includes corresponding Graph/Chart) III-3
Medtronic - The Insulin Pumps Major III-3
Table 11: US Insulin Pumps Market (2008): Percentage Share
Breakdown of Leading insulin Pump Manufacturers -
Medtronic, Animas and Others Comparison of Major Insulin
Pump Systems Based on Select Parameters (includes
corresponding Graph/Chart) III-3
Product Introductions III-4
Strategic Corporate Developments III-5
Major Players III-10
B.Market Analytics III-15
Table 12: US Recent Past, Current & Future Analysis for
Insulin Delivery Systems - Insulin Syringes, Insulin Pens
and Insulin Pumps (External) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) III-15
Table 13: US Historic Review for Insulin Delivery Systems -
Insulin Syringes, Insulin Pens and Insulin Pumps (External)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-15
Table 14: US 10-year Perspective for Insulin Delivery
Systems - Percentage Breakdown of Value Sales for Insulin
Syringes, Insulin Pens, and Insulin Pumps (External) Markets
for Years 2003, 2009 & 2015 (includes corresponding
Graph/Chart) III-16
2. EUROPE III-17
A.Market Analysis III-17
European Preference for Insulin Pens Overshadows the Rest of
the World Demand III-17
Insulin Pump Therapy Gaining Favor Among Europeans III-17
Strategic Corporate Developments III-18
Major Players III-19
B.Market Analytics III-21
Table 15: Europe Recent Past, Current & Future Analysis for
Insulin Delivery Systems - Insulin Syringes, Insulin Pens
and Insulin Pumps (External) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) III-21
Table 16: Europe Historic Review for Insulin Delivery
Systems - Insulin Syringes, Insulin Pens and Insulin Pumps
(External) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-22
Table 17: Europe 10-year Perspective for Insulin Delivery
Systems - Percentage Breakdown of Value Sales for Insulin
Syringes, Insulin Pens, and Insulin Pumps (External) Markets
for Years 2003, 2009 & 2015 (includes corresponding
Graph/Chart) III-23
3. REST OF WORLD III-24
A.Market Analysis III-24
Product Introductions III-24
Strategic Corporate Developments III-26
Major Players III-27
B.Market Analytics III-28
Table 18: Rest of World Recent Past, Current & Future
Analysis for Insulin Delivery Systems - Insulin Syringes and
Insulin Pumps (External) Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) III-28
Table 19: Rest of World Historic Review for Insulin Delivery
Systems - Insulin Syringes and Insulin Pumps (External)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-29
Table 20: Rest of World 10-year Perspective for Insulin
Delivery Systems - Percentage Breakdown of Value Sales for
Insulin Syringes and Insulin Pumps (External) Markets for
Years 2003, 2009 & 2015 III-29
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 72 (including Divisions/Subsidiaries - 82)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 34
Canada 2
Japan 2
Europe 10
France 1
Germany 1
The United Kingdom 2
Rest of Europe 6
Asia-Pacific (Excluding Japan) 31
Middle-East 3
------------------------------------------
To order this report:
Drug Delivery Technology Industry: Global Insulin Delivery Systems industry
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article